Harrington Scholar Award for Coronavirus
Request for Proposals

Application Deadline: Thursday, April 30, 2020 5:00 PM EDT

The Harrington Scholar Award for Coronavirus is a transatlantic call for proposals for new treatments to support the global fight against novel Coronavirus and potential future pandemic events. Harrington Discovery Institute will provide successful applicants with grant funding and expert guidance and oversight in all aspects of drug development, while taking no rights to intellectual property, which is retained by the award recipient and their institution.

HDI will select up to ten projects through the call for proposals and its current portfolio of drugs in development. Awarded projects will run for 12 months, with the possibility of extending the engagement.

Submission instructions:
1. Complete ‘Application Questions’, which can be downloaded from the HDI website.
2. Develop the following:
   - Project description (three-page maximum)
   - Key data (one-page)
   - References (one-page)
3. Include biographical sketch in the NIH format (OMB No. 0925-0001/0002 Rev. 10/15)
4. Combine eligibility and application questions, project description, key data, references and biographical sketch into a single PDF document.
5. Email the final document to Rebecca.Koopman@HarringtonDiscovery.org with “Coronavirus Grant” in the subject line by Thursday, April 30, 2020 at 5:00 PM EDT.

Applicants will receive an email confirmation of their submission.

Projects being sought:

- Novel therapies that can target coronavirus and its co-morbidities, such as impact on lungs and heart.
- Broad-spectrum anti-viral therapies, particularly targeting respiratory viruses.
- Next generation vaccines that may target new corona strains, multiple corona viruses or more than one type of virus.
- Emergency countermeasures/prophylaxis strategies for first responders and emergency medical personnel to be administered either once or short-term.
Emphasis of call:

- Therapies that can enter clinical trials near-term (i.e., within 12 months) with HDI project management and financial support.
- Breakthrough, differentiated technologies and discoveries.

Who is eligible?

- Investigators from accredited academic medical centers, research institutions or universities in the U.S., Canada and the United Kingdom.
- Lead investigators must have an M.D. or Ph.D. or equivalent.

Multi-level support for award recipients includes:

- $150k guaranteed, with the potential to receive up to $1 million in charitable support.
- Dedicated drug discovery and development support from Harrington Discovery Institute’s Therapeutics Development team (experienced pharma and business development team with a track record of bringing new drugs to market).
- A personalized team of drug developers and project manager for every award recipient.
- Select access to partners that range from non-profit, foundation, and public sector organizations to private drug development and investment companies.

Depending on the project’s needs, the award may also include:

Technology Development support related to…

- Medicinal chemistry
- Formulation
- Pharmacokinetics, pharmacodynamics and toxicology
- Regulatory strategy
- Structural biology and biophysics
- Pre-clinical and clinical planning
- Access to contract research organizations/service providers

Business Development support related to…

- Market analysis
- Intellectual Property management
- Commercialization strategy
- Access to fundraising and investor network
- Grant-writing
- Pitch preparation and coaching
- Deal negotiation
- Company formation
Note that…

- The HDI Therapeutics Development team will work with successful applicants to redirect promising therapies toward Coronavirus if applicable.
- Funding from other sources (e.g. DoD, NIH, foundations) is welcomed but not required.
- All therapeutic modalities will be considered.

Confidentiality

Harrington Discovery Institute review panel members complete Confidentiality and Non-Disclosure Agreements to protect confidential applicant submissions. Non-public applicant information is always kept confidential (and limited in distribution to the reviewers and Harrington Discovery Institute administrative team). For those selected as Harrington Scholars, and with the award recipient’s approval, the abstract summary may be used by Harrington Discovery Institute for publicity and marketing purposes (on the Harrington Discovery Institute website, news releases, etc.). A Harrington Scholar’s name, institutional affiliation and award name may be used at Harrington Discovery Institute’s sole discretion.

Applicants acknowledge that University Hospitals Health System may conduct research that is related to, or competitive with, proposals submitted by applicants, but University Hospitals Health System commits not to use information submitted by applicants in connection with research.

Intellectual Property

Harrington Discovery Institute does not claim rights to patents on discoveries, copyrights or trademarks to other intellectual property created as a result of work conducted through the Harrington Scholar Award for Coronavirus program. On all aspects of Intellectual Property, Principal Investigators are encouraged to confer with their technology transfer office and/or office of sponsored programs for guidance. Awardees should take measures to ensure protection of any Intellectual Property, if appropriate, and then are required to make prompt disclosure of discoveries to the public.

For more information visit, please visit: HarringtonDiscovery.org/Coronavirus.

Questions? Send an email to HDIQuestions@HarringtonDiscovery.org.